![MERZ [Logo]](skin_img/skin_logo-screen.gif){kind=logo}
We Care. Research for your Health.
Management
Jack Britts President & CEO
Robert W. Burgess Chief Financial Officer & Vice President Administration
Bhushan Hardas, MD Vice President, Medical & Regulatory Affairs
Dave Shoup Vice President, Neurology
Jack Britts, President and Chief Executive Officer, joined Merz Pharmaceuticals in September 2008 and brings with him a wealth of experience developed during a multi-faceted pharmaceutical career.
Prior to joining Merz, Jack spent 7 years at Sepracor, where he headed the majority of commercial activities, including Marketing, Organized Customer Strategy, Contracting and Sales, Government Affairs, Commercial Analytics, and New Products Planning. From 1986 to 2000, Jack held various positions within AstraZeneca PLC, where he last served as Vice President, Therapeutic Area Leader Gastrointestinal Products with responsibility for over $4.5 billion in sales. Prior to the AstraZeneca merger, Jack held a number of positions within Zeneca, including Sales, Marketing, Product and Portfolio Management, as well as an international assignment serving as the General Manager for the businesses in Central and Eastern Europe, Turkey, Middle East, and Africa with Zeneca Pharma International.
Jack holds a BS in Economics from the University of Richmond.
Robert W. Burgess, CPA, Chief Financial Officer & Vice President Administration for Merz Pharmaceuticals, LLC, has been with Merz and its predecessor, Mayrand Pharmaceuticals, for 16 years. Burgess joined the company as Secretary/Treasurer in 1991 and worked with Goody’s Pharmaceuticals, Mayrand’s parent company, in a joint capacity from 1992 to 1995. Prior to working for Mayrand, Burgess held positions as General Staff, Senior Staff, Manager, and Senior Manager with McGladrey & Pullen, a national public accounting firm.
Burgess is also CFO and Vice President of Administration of Merz Inc., the parent/holding company of Merz Pharmaceuticals LLC, and its affiliate Senator USA, LLC and serves as a member of the board of directors of Merz, Inc.
Burgess holds a BS/BA with a concentration in accounting from the University of North Carolina at Chapel Hill. He obtained his CPA certification in 1984 and is a member of the American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants.
Bhushan
Hardas, MD, MBA, Vice President
of US Research & Development
joined Merz Pharmaceuticals, LLC in 2004 to oversee all medical, regulatory
and quality functions. Prior to joining Merz, Dr. Hardas was director
of dermatology at Procyon Biopharma, Inc., a Montreal-based Canadian
biotechnology company, where he led the scientific, medical and clinical
activities supporting all aspects of the company's dermatology business.
Earlier, Dr. Hardas also spent eight years at Derm Cosmetic Labs, advancing
to the position of research and development executive director.
Dr. Hardas received advanced training in clinical immunology and molecular
biology at King's College London at the University of London, in London,
England. He also completed a research fellowship in the Department
of Dermatology at the University of Michigan, and received his MBA
in healthcare management from the University of California - Irvine.
His work in skin biology has been published in the Journal of Investigative Dermatology and the Journal of Dermatology, and he has been recognized by the Dermatology Foundation, the Veteran's Administration and the National Institute of Health.
Dr. Hardas's professional affiliations include memberships in American Academy of Dermatology, Wound Healing Society, and the U.S.-based Regulatory Affairs Professional Society. He is a patron member of Society for Investigational Dermatology, a member of the leaders society at the Dermatology Foundation, as well as the Molecular Biology Cancer Network, and Royal Society of Medicine based in the United Kingdom.
Dave Shoup, Vice President of Neurology, joined Merz Pharmaceuticals in October 2008 to lead Merz US’ entry into the neurology market. Dave brings to Merz 22 years of experience in the pharmaceutical/biotech industry, having most recently served as Vice President of Marketing for the TPR division of Talecris Biotherapeutics, where he established marketing and customer analytics functions within the organization. Dave also served as Vice President of Global Commercial Development at Talecris, with responsibility for developing lifecycle management programs and overseeing marketing research and portfolio management.
Prior to Talecris, Dave served as Global Alliance Leader, Global Product Team Leader and Vice President of Sales and Marketing for EMD Pharmaceuticals (an affiliate of Germany’s Merck KGaA) as well as in a variety of commercial management roles during a fifteen-year career with AstraZeneca Pharmaceuticals.
Dave holds a BA in Telecommunications/Marketing from Indiana University.
The product information provided herein is intended for US residents only.